All Activity

It's so inspiring to read about Dutch Valley Farms and their commitment to sustainable practices and quality cannabis! It’s heartwarming to see a family-owned farm making such a positive impact not only in the cannabis community but also for families dealing with similar challenges. Their approach to farming and research is truly admirable. By the way, if you enjoy games with a bit of thrill, you might want to check out Snow Rider 3D for some fun escapism!

Ohio activists are launching a campaign to hit the brakes on a bill the governor recently signed to scale back the state’s voter-approved marijuana law and ban the sale of consumable hemp products outside of licensed cannabis dispensaries. Ohioans for Cannabis Choice said on Friday that they’d be collecting signatures for the statewide referendum, which would pause the implementation of SB 56 until voters got a say at the next regular or general election. Gov. Mike DeWine (R) has been adamant about cracking down on the unregulated intoxicating hemp market, but the legislation he signed would do more than restrict the sale of cannabinoid products to dispensaries. It would also recriminalize certain marijuana activity that was legalized under the ballot initiative voters approved in 2023, and it’d additionally remove anti-discrimination protections for cannabis consumers that were enacted under that law. The governor also used his line-item veto powers to cancel a section of the bill that would have delayed the implementation of the ban on hemp beverages. Advocates and stakeholders strongly protested the now-enacted legislation, arguing that it undermines the will of voters and would effectively eradicate the state’s hemp industry, as there are low expectations that adults will opt for hemp-based products over marijuana when they visit a dispensary. The pushback inspired the newly filed referendum—but the path to successfully blocking the law is narrow. Ohioans for Cannabis Choice must first collect an initial batch of 1,000 valid signatures, which would need to be certified by the secretary of state’s office, and then submit a total of about 250,000 signatures to make the ballot. “SB 56 forcefully defies the will of the voters of Ohio, who spoke clearly on this issue, and denies the people of Ohio the freedom to use these products for their personal use,” Dennis Willard, spokesperson for the campaign, said. “We are launching a referendum campaign to go directly to the voters,” he said. “We believe voters will say no to government overreach, no to closing 6,000 small businesses and pink-slipping thousands of workers across the state, and no to once again recriminalizing hemp and marijuana.” If activists reach the signature threshold by the deadline three months from now, which coincides with the same day the restrictive law is to take effect, SB 56 would not be implemented until voters got a chance to decide on the issue at the ballot. Advocates have flagged a series of concerns with the law, pointing out, for example, that it would eliminate language in statute providing anti-discrimination protections for people who lawfully use cannabis. That includes protections meant to prevent adverse actions in the context of child custody rights, the ability to qualify for organ transplants and professional licensing. It would also recriminalize possessing marijuana from any source that isn’t a state-licensed dispensary in Ohio or from a legal homegrow. As such, people could be charged with a crime for carrying cannabis they bought at a legal retailer in neighboring Michigan. Additionally, it would ban smoking cannabis at outdoor public locations such as bar patios—and it would allow landlords to prohibit vaping marijuana at rented homes. Violating that latter policy, even if it involves vaping in a person’s own backyard at a rental home, would constitute a misdemeanor offense. The legislation would also replace what had been a proposed regulatory framework for intoxicating hemp that the House had approved with a broad prohibition on sales outside marijuana dispensaries following a recent federal move to recriminalize such products. Under the law, hemp items with more than 0.4 mg of total THC per container, or those containing synthetic cannabinoids, could no longer be sold outside of a licensed marijuana dispensary setting. That would align with a recently enacted federal hemp law included in an appropriations package signed by President Donald Trump. The federal law imposing a ban on most consumable hemp products has a one-year implementation window, however, and it appears the Ohio legislation would take effect sooner. As passed by the legislature, a temporary regulatory program for hemp beverages would have stayed in place in Ohio until December 31, 2026, but that provision was vetoed by the governor. The law also includes language stipulating that, if the federal government moves to legalize hemp with higher THC content, it’s the intent of the Ohio legislature to review that policy change and consider potential state-level reforms to regulate such products. The bill signing came months after DeWine issued emergency rules prohibiting the sale of intoxicating hemp products for 90 days, with instructions to the legislature to consider permanent regulations. A county judge has enjoined the state from enforcing that policy in response to a legal challenge. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, in September, the Ohio Department of Cannabis Control (DCC) filed proposed rules to build upon the state’s marijuana legalization law, laying out plans to update regulations on labeling and packaging requirements. The proposal came weeks after Ohio medical and adult-use marijuana sales officially crossed $3 billion, data from the state Department of Commerce (DOC) shows. The state sold about $703 million in recreational cannabis in the law’s first year of implementation, according to DCC data. In March, a survey of 38 municipalities by the Ohio State University’s (OSU) Moritz College of Law found that local leaders were “unequivocally opposed” to earlier proposals that would have stripped the planned funding. Meanwhile in Ohio, adults as of June are able to buy more than double the amount of marijuana than they were under previous limits, with state officials determining that the market can sustainably supply both medical cannabis patients and adult consumers. The governor in March separately announced his desire to reallocate marijuana tax revenue to support police training, local jails and behavioral health services. He said funding police training was a top priority, even if that wasn’t included in what voters passed in 2023. The post Ohio Activists Plan Referendum To Block New Law Rolling Back Marijuana Rights And Restricting Hemp Sales appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A top Trump administration health official said last week that his agency will soon launch a novel program to have Medicare cover the costs of CBD for certain patients. But while the administration has not yet released specific details about the initiative’s rollout, one cannabis company that says it’s partnering with the government on the effort has since shed some light on what to expect. At a White House event last week, President Donald Trump signed an executive order directing the attorney general to complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). But another major reform was also announced: A pilot program enabling eligible patients to access hemp-derived cannabidiol that’d be covered under federal health insurance plans, projected to launch by April. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS), spoke about the initiative at the signing ceremony, crediting Trump and U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for “pushing for change” and “relentlessly” pursuing an agenda rooted in a “deep passion for research.” Oz said Trump called him “frequently” to discuss the potential benefits of CBD after hearing from friends who “got relief” from the cannabinoid product, and per his direction, CMS has created “a new model” and taken “additional actions to give seniors access to cannabinoids.” “These are CBDs—they’re not addictive—which many are already using to manage pain,” he said. “There’s some clinical evidence that showing that CBDs provide relief from common conditions that affect Americans, including cancer symptoms and chronic pain and a slew of other problems that affect disproportionately seniors and our veterans.” There are relatively few specific details about the new model, however, and the CMS website hasn’t yet posted information about the rollout or who would specifically qualify. That said, Oz explained that the policy change will “allow millions of Americans on Medicare to become eligible to receive CBD as early as April of next year—and at no charge if their doctors recommend them.” One outstanding question concerns coverage eligibility. As described, it would affect those 65 and older who qualify for Medicare, but the specific qualifying conditions weren’t detailed. There was repeated mention of chronic pain, specifically related to cancer, but it’s possible the CBD eligibility criteria includes additional conditions. Marijuana Moment reached out to CMS for additional clarity about the plan, but representatives did not respond by the time of publication. At the Oval Office event, Oz said “sometimes these decisions are difficult,” and that while other presidents have “whiffed on this issue” because it’s “tough,” this administration is “passionate about making it clear that this patchwork that we’re working within now, the laws and regulations, they’re leaving patients and doctors without adequate guidance on the safeguards of how to use these products, even though they’re still being used.” The administrator added that Medicare Advantage insurers CMS has contacted are “also agreeing to consider CBD to be used for the 34 million Americans that they cover.” “If you can hear my voice and you’re over 65, you should pay attention to this executive order, because it’s going to touch your life,” Oz said. “Again, this all becomes active after the first quarter of next year. These CBD products must first meet local and state quality and safety standards. They must come from legitimate sources. They must abide by other regulations of those states with these boxes checked.” He said patients can be reimbursed for up to $500 worth of hemp-derived cannabinoid products per year, and CMS will be collecting data on the patient outcomes and making the data publicly available to analyze. “If it shows promise, we will expand access to these products to even more conditions amongst Medicare [and] Medicaid beneficiaries,” he said. Oz also gave kudos to Howard Kessler, founder of The Commonwealth Project, which produced a video about the benefits of cannabidiol for seniors that Trump shared on Truth Social earlier this year and who apparently has pressed the president to enact reform to expand cannabis access. One company that says it will be participating in the CBD pilot program is Charlotte’s Web, which has long advocated for reform and focused on the therapeutic potential of cannabinoids for people with severe epilepsy. CEO Bill Morachnick said in a press release that the business is “proud” to “bring trusted CBD options to underserved seniors battling cancer” through the initiative. “Charlotte’s Web was founded to help Charlotte Figi, whose medically challenging life became a CBD success story,” he said. “Her journey inspired research, opened doors to access, and changed perceptions about the therapeutic benefits of CBD around the globe.” “The Company made a promise to Charlotte, her mother Paige, and the millions who followed her: to set the standard for the entire industry by leading with quality, consistency, and science,” he said. “As the CBD market leader and a trusted partner throughout the country among healthcare practitioners, this initiative marks a historic step forward, uniquely positioning Charlotte’s Web to expand access to safe, non-intoxicating hemp CBD products through existing pathways.” “This initiative represents a blueprint for patient-centered CBD healthcare—one that advances alongside our medical channel expansion and deepening clinical research. The potential of the hemp plant is still being furthered, and studies like the Phase 2 FDA clinical trials investigating hemp-based therapies for autism spectrum disorder at our affiliated company, DeFloria, are critical to making its therapeutic promise even more accessible for health insurance-covered care. Our work through this program and our ongoing research demonstrate how rigorous science and compassionate care can converge to serve patients who need it most.” “This pilot program would inform potential expansion into other patient populations to use CBD to support sleep, anxiety, pain, and general wellness as identified in the Federal Register,” the company said, referencing a recent notice from CMS about its existing plans to authorize health insurance coverage for CBD under certain Medicare programs. While CMS implemented an earlier 2026 final rule in April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency has since revised that policy. The Commonwealth Project estimates that 8,000-12,000 patients will participate in the program, with projections of up to $64 billion in “potential annual savings through improved symptom management and reduced reliance on certain high-cost interventions,” according to information in a press pitch on behalf of Charlotte’s Web. While Oz said April 2026 is when eligible patients will be able to take advantage of the policy change, the hemp stakeholders’ press pitch said the pilot program itself is set to launch in January. Marcel Bonn-Miller, chief scientific officer at Charlotte’s Web, said “scientific rigor underpins every aspect of this program.” “With more than a decade of consumer use and extensive safety studies, Charlotte’s Web integrates real-world evidence, patient-reported outcomes, and clinical insights into its R&D process to ensure products are safe and effective,” he said. Meanwhile, following the White House announcement last week, Oz spoke with NewsNation about the policy change, responding to a question about how the broader marijuana rescheduling decision squares with the Trump administration’s aggressive efforts to stymie the flow of other illicit drugs, particularly fentanyl. “We think they fit hand in hand,” he said. “This is really about researching—specifically CBD, which is hemp-derived endocannabinoids [sic]—are actually worthy of Americans using them,” he said. “It’s hard to do some of this work, especially with medical marijuana. And this is not about legalization of marijuana.” “There is no legalization language at all,” he added. “It’s about rescheduling this class of product so that it can be researched more readily.” The idea that marijuana has no medical value, as its currently defined as a Schedule I drug, is “just patently wrong for marijuana,” he said, noting that the Food and Drug Administration (FDA) has approved certain cannabis-based drugs for conditions such as epilepsy “that work quite nicely.” “That belief that it should be Schedule I is just an incorrect place to put it,” he said. “Schedule III seemed to make sense to the president. He argued that it allows us to do the research more readily.” “We’re finding a way to allow Medicare beneficiaries to get access to some of these products. And so, within Medicare, we have the ability, for the first time ever—and we delivered on this promise to the president today—to allow doctors to recommend hemp-derived CBD for patients who have cancer, for example, and have a lot of pain from that.” The administrator said surveys show a majority of seniors who take CBD for pain management find it beneficial, and the White House wants to “make it easier for patients to access this” and allow them to access the cannabinoid at “no charge” through the federal health insurance program. “If it works well, we’re going to get a lot of data—and we’ll know a ton more about whether this truly makes a difference for the American people,” Oz said. “But again, I want to emphasize this: I don’t like marijuana smell walking down the streets. The president doesn’t either.” Trump and Kennedy “don’t drink, so they definitely don’t smoke marijuana. So this is not about legalizing these products,” he said. In recent years, Dr. Oz has encouraged audiences to be open to therapeutic cannabis and advocated for sweeping policy changes around the drug. “We ought to completely change our policy on marijuana. It absolutely works,” he said in a 2020 interview, calling cannabis “one of the most underused tools in America.” Last year, he wrote in a syndicated health column that there’s evidence cannabinoids can curb seizures, alleviate nausea associated with cancer treatment and potentially help manage pain—especially in older people. Oz also said in 2020 that he believes that, particularly for seniors, marijuana for pain represents a “safer solution than, for example, narcotics in many cases.” The post Federal Health Programs Will Cover Up To $500 Worth Of CBD For Certain Patients By April, Trump Official Dr. Oz Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Awesome and interesting article. Great things you've always shared with us. Thanks. Just continue composing this kind of post. <a href="https://www.awfenceworks.com/blog/">situs togel</a>

“Law enforcement officers, first responders and veterans carry real trauma, and too many run out of options.” By Jack Gorsline, Psychedelic State(s) of America In a historic move on Friday, the Massachusetts Joint Committee on Public Health voted to advance two pivotal pieces of legislation regarding psilocybin, marking a significant shift in the state’s approach to psychedelic medicine. Specifically, lawmakers voted to advance H.2532, a bill establishing a framework for psilocybin therapy, alongside a new draft of H.2506, a measure designed to legalize the use of psilocybin specifically for veterans, law enforcement officers and qualifying patients. The vote represents the first time a committee in the Massachusetts legislature has approved psilocybin legalization, setting a new precedent for drug policy reform in the commonwealth. The committee’s decision was bipartisan and nearly unanimous. According to committee staff, 10 of the 11 members voted in favor of the proposal, with only a single lawmaker abstaining. Notably, the “yes” votes included Air Force veterans Rep. Shirley Arriaga (D) and Rep. Justin Thurber (R), underscoring the legislation’s strong appeal among those familiar with the mental health challenges facing service members. A Patient-First Approach The advancement of these bills comes in the wake of the scandal-plagued, ultimately-failed 2024 psychedelics ballot question, which sought to legalize widespread recreational use and distribution. While that measure was rejected by voters, the legislation advanced Friday takes a markedly different, “patient-focused” approach. H.2506 was primarily authored by Graham Moore of the advocacy group Mass Healing, in collaboration with Rep. Steven Owens (D). The bill was drafted in consultation with a psychiatrist from the Massachusetts Psychiatric Society (MPS) and two pharmacists, ensuring the language prioritized medical safety and targeted relief for specific vulnerable populations rather than broad open access. “Whatever the merits of taking psilocybin ‘for fun,’ it is a distinct issue from whether individuals with cancer or severe depression should be dragged through the courts for seeking relief,” said Moore, reflecting on the legislative victory. “The ballot question last year was a politically irresponsible experiment to decriminalize recreational use on the backs of patients like me, who campaigned for it for lack of a better alternative. But unlike the out-of-state architects of the failed ballot question, patients in Massachusetts cannot afford to stop fighting.” Historic Momentum for Mental Health The Joint Committee on Public Health’s vote is the latest in a series of historic developments for psychedelic policy in Massachusetts this year. In January, Mass Healing’s leadership worked with state lawmakers to file a record number of psychedelic proposals. To date, four of the 11 bills filed have been reported favorably out of committee, with none tabled—a high success rate for such a novel policy area. In July, the Massachusetts Psychiatric Society formally endorsed three psilocybin decriminalization bills. This endorsement marked the first time any branch of the American Psychiatric Association (APA) nationwide has formally backed such legislation, signaling a shift in the medical community’s willingness to explore psychedelic adjunctive therapies. Additionally, in August, the Joint Committee on Mental Health, Substance Use and Recovery approved a psychedelic therapy bill, further paving the way for the Public Health Committee’s recent action. Voices from the Frontlines The push for H.2506 has been heavily driven by those on the front lines of trauma: veterans and first responders. Mass Healing volunteers spent months organizing support, culminating in an outpouring of written testimony from residents, psychiatrists and public safety officials. Lt. Sarko Gergerian, a police lieutenant and member of the Law Enforcement Action Partnership (LEAP), emphasized the practical benefits of the legislation for public safety and mental health. “I am so grateful to the Joint Committee on Public Health for their wisdom and compassion in advancing a psilocybin therapy pilot bill in combination with long overdue protections for vulnerable patients,” Gergerian said. “Law enforcement officers, first responders and veterans carry real trauma, and too many run out of options. This evidence-based proposal honors those who serve, advances science and frees up police resources for where they are needed most.” Gergerian, who holds master’s degrees in counseling and criminal justice, also thanked Committee Chair Marjorie Decker for her leadership. “With Chair Decker’s recommendation, the public health committee has sent a resounding message: healing should not be a crime,” he added. Broad Coalition of Support A diverse coalition spanning veterans’ rights, healthcare and criminal justice reform has rallied behind the legislation, lending significant political weight to the proposal. Among the most notable endorsements is from Disabled American Veterans (DAV), which represents more than 60,000 disabled veterans across the commonwealth. Their support is bolstered by advocacy groups focused on the suicide epidemic among service members, including the Massachusetts-based Minus 22 Foundation and the No Fallen Heroes Foundation, whose founder, U.S. military veteran Matthew “Whiz” Buckley, recently highlighted the potential of psychedelic therapies during an appearances at Harvard University’s Petrie-Flom Center. Beyond the veteran community, the bill has secured critical backing from law enforcement and patient advocacy groups, challenging traditional narratives around drug policy. The Law Enforcement Action Partnership (LEAP), a national nonprofit of police, prosecutors and judges, has formally endorsed the measure, emphasizing the need to support officers and first responders carrying trauma. Additionally, Clusterbusters, a national organization representing patients with cluster headaches, has thrown its support behind the bill, citing the responsiveness of their notoriously treatment-resistant condition to psilocybin in early clinical reports. National Significance Friday’s vote distinguishes Massachusetts as a national leader in targeted drug policy reform. While other states like Oregon and Colorado have moved toward broader legalization or regulated access models, the Massachusetts legislature is the first to have a committee approve a strictly patient-focused legalization bill. A similar attempt in the Michigan legislature failed to advance out of committee earlier this session. Observers suggest that the Massachusetts model—pairing clinical research frameworks (H.2532) with immediate legalization for those with medical needs (H.2506)—could serve as a blueprint for other states where voters or lawmakers are wary of full recreational legalization but sympathetic to the mental health crisis. Looking Ahead The bills now move to the next stage of the legislative process, where they must pass through further committees and eventually floor votes in both the House and Senate. Advocates remain optimistic. Mass Healing’s Moore and Morey have expressed hope that the continued support of legislative thought leaders—including Rep. Marjorie Decker (D), Rep. Jim O’Day (D), Sen. Cindy Friedman (D), Rep. Lindsay Sabadosa (D) and Rep. Steven Owens (D)—will steer the bills to final passage. For the veterans and patients waiting for legal clarity, the committee’s vote is more than a procedural step; it is a validation of their struggle. By stripping away the threat of prosecution for those seeking healing, Massachusetts lawmakers are acknowledging that for many, psilocybin is not a party drug, but a lifeline. This article was produced by Psychedelic State(s) of America – a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Subscribe to PSA online and Follow PSA on Instagram, LinkedIn, Twitter/X, Facebook. Learn more about PSA and donate to the PSA Media Fund here. Image courtesy of CostaPPR. The post Massachusetts Lawmakers Vote To Legalize Psilocybin And Establish Framework For Therapeutic Access appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Wonderful posting, Thanks a ton to get spreading The following awareness. Wonderfully authored posting, doubts all of blog owners available precisely the same a higher standard subject material just like you, online has got to be improved site. I highly recommend you stay the best! 99dewa pkv

Florida lawmakers have filed new bills for the 2026 session that would reduce medical cannabis patient registration fees for military veterans and clarify that smoking or vaping marijuana in public places is prohibited. Sen. Keith Truenow’s (R) proposal would make it so that veterans would only need to pay a $15 state fee to receive, renew or replace a medical marijuana patient ID card. That’s a significant reduction from the standard rate of $75. In order to prove eligibility under the bill, the patient would need to provide a Certificate of Release or Discharge from Active Duty form from the military, a Department of Veterans Affairs identification card or a Florida driver license bearing the veteran designation. Rep. Susan Valdes (R) is sponsoring a companion measure in the House of Representatives. The other new bill, from Sen. Joe Gruters (R), would ban smoking or vaping cannabis in public places. The legislation defines a public place as “a place to which the public has access, including, but not limited to, streets; sidewalks; highways; public parks; public beaches; and the common areas, both inside and outside, of schools, hospitals, government buildings, apartment buildings, office buildings, lodging establishments, restaurants, transportation facilities, and retail shops.” The measure from Gruters, who is also chairman of the Republican National Committee, would also specify that marijuana cannot be smoked or vaped in customs smoking rooms at airports. Rep. Alex Andrade (R) filed a similar bill to ban public cannabis smoking last month. The new proposals are among a growing list of cannabis legislation that lawmakers are introducing for consideration next year. Earlier this month, Rep. Bill Partington (R) introduced a bill to expand the state’s medical marijuana program in a number of ways, including by allowing doctors to recommend cannabis to any patient who has a condition for which they have been prescribed opioids. It would also make it so medical marijuana registrations could last up to two years instead of the current 30 weeks, and it’d waive patient registration fees for honorably discharged military veterans. Under the proposal, doctors would additionally be able to recommend medical cannabis via telehealth without a physical examination—expanding a current policy that allows renewals, but not initial certifications, to be conducted remotely. There are also reciprocity provisions built into the measure, requiring regulators to create a process to issue medical cannabis registration cards to “nonresidents who are actively enrolled in the medical cannabis program of another jurisdiction recognized by the department within 1 business day.” It specifies that “a visiting qualified patient may engage in all conduct authorized for a qualified patient.” Another section of the bill stipulates that doctors could certify patients to receive up to 10 70-day supply limits of smokable medical marijuana, rather than three. They could also issue up to 20 35-day supply limits instead of the current six. That measure was filed just days after a Florida Democratic senator introduced legislation for the 2026 session that would legalize home cultivation of marijuana for registered medical cannabis patients in the state. The proposal would permit qualified patients who are at least 21 years old to cultivate up to six flowering plants for personal, therapeutic use. Those patients could also buy seeds and clones from licensed dispensaries. The legislative proposals come as the state’s attorney general is asking the Florida Supreme Court to review the constitutionality of a marijuana legalization initiative that an industry-funded campaign is seeking to place on the 2026 ballot. A similar measure on the 2024 ballot received majority voter support but did not reach the 60 percent threshold required for enactment under state law. In March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to Gov. Ron DeSantis (R). The money was used to fight against the 2024 initiative. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said in February that the newest marijuana legalization measure is in “big time trouble” with the state Supreme Court, predicting it will be blocked from going before voters next year. “There’s a lot of different perspectives on on marijuana,” DeSantis said. “It should not be in our Constitution. If you feel strongly about it, you have elections for the legislature. Go back candidates that you believe will be able to deliver what your vision is on that.” “But when you put these things in the Constitution—and I think, I mean, the way they wrote, there’s all kinds of things going on in here. I think it’s going to have big time trouble getting through the Florida Supreme Court,” he said. The latest initiative was filed with the secretary of state’s office just months after the initial version failed during the November 2024 election—despite an endorsement from President Donald Trump. Smart & Safe Florida is hoping the revised version will succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” Last year, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released in February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In the background, a recent poll from a Trump-affiliated research firm found that nearly 9 in 10 Florida voters say they should have the right to decide to legalize marijuana in the state. Separately, Florida medical marijuana officials are actively revoking the registrations of patients and caregivers with drug-related criminal records. The policy is part of broad budget legislation signed into law earlier this year by DeSantis. The provisions in question direct the state Department of Health (DOH) to cancel registrations of medical marijuana patients and caregivers if they’re convicted of—or plead guilty or no contest to—criminal drug charges. Photo courtesy of Chris Wallis // Side Pocket Images. The post Florida Bills Would Reduce Medical Marijuana Fees For Military Veterans And Ban Public Smoking appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Inside Trump’s marijuana meeting; State AGs tell SCOTUS: Keep cannabis user gun ban; Fed study: Teen marijuana use “stable”; Cannabis & holidays Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… By starting a $10 per month pledge on Patreon—or about 45 cents per issue of this newsletter—you can help us rely less on ads to cover our expenses, hire more journalists and bring you even more marijuana news. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. John Hickenlooper (D-CO) filed a marijuana bill that would direct the attorney general to form a commission to prepare for federal legalization by recommending cannabis regulations modeled after those currently in place for alcohol. Scotts Miracle-Gro CEO Jim Hagedorn revealed details about an “insane” marijuana rescheduling meeting in the Oval Office at which he said President Donald Trump described a compromise to put cannabis in Schedule II as a “half-assed” alternative to Schedule III. Attorneys general from 19 states and Washington, D.C. filed a brief asking the U.S. Supreme Court to uphold the federal law restricting marijuana consumers’ gun rights—saying that lower court rulings against the ban are “flawed in multiple respects.” The latest results of the federally funded Monitoring the Future survey show that teen marijuana use “remained stable” last year—even as more states continue to legalize cannabis—and that it is lower now than before states started enacting the reform. State marijuana regulators are offering guidance about how to legally gift marijuana for the holidays and stay safe while celebrating. / FEDERAL The Drug Enforcement Administration promoted a podcast about the role of athletics in supporting drug prevention. Rep. Eleanor Holmes Norton (D-DC) inserted comments into the Congressional Record about her bill to protect people from being evicted from public housing for marijuana use. Rep. Sydney Kamlager-Dove (D-CA) tweeted, “Transferring cannabis from Schedule I to Schedule III is a meaningful step toward decriminalization. Last year, I urged the Biden Administration to reclassify marijuana, and I was encouraged when they began the rescheduling process. While I welcome this administration’s continuation of that work, I will continue to closely monitor the rule-making process and assess the rescheduling’s impact on expungements, advocate for protections for small businesses against industry consolidation, and ensure this progress is used to reinvest in our local communities—especially those most harmed by the War on Drugs.” Rep. Jared Huffman (D-CA) filed a bill that includes provisions to rehabilitate lands damaged by illegal marijuana growing operations. Rep. Tom McClintock (R-CA) tweeted, “Pot is a bad idea. So is criminalizing it. In a free society, grownups should make these decisions for themselves. Kudos to Trump for his EO today. Congress should finish the job.” / STATES New York Gov. Kathy Hochul (D) signed kratom regulation legislation. Nevada Gov. Joe Lombardo (R) announced a new chair of the Cannabis Compliance Board. South Dakota’s attorney general said rescheduling marijuana can boost research. New Jersey lawmakers sent Gov. Phil Murphy (D) a bill to ban intoxicating hemp product sales. Wisconsin’s Senate president said her chamber is “closer than ever” to voting on medical cannabis legislation, but said the chances of the Assembly advancing the issue are “slim.” A Delaware representative filed a bill to make consumption of marijuana in public places or in a moving vehicle a civil violation rather than a misdemeanor. Rhode Island regulators filed proposed changes to marijuana rules. Michigan regulators published a monthly report on disciplinary actions taken against marijuana businesses. California regulators said President Donald Trump’s marijuana rescheduling order is “a significant step toward grounding federal cannabis laws in evidence rather than stigma and fear.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Jersey’s minister for health and social services is asking lawmakers to choose between three marijuana reform options ahead of a debate scheduled for February 3. / SCIENCE & HEALTH A study found that “CBD reduced prostate cancer cell viability and proliferation, with the therapeutic potential to synergise with targeted therapies.” A study of dental extraction patients found that “higher-concentration CBD (37 mg/mL) may provide analgesia comparable to standard non-opioid therapy.” A study found that “psilocybin reduces comorbid chronic pain and depression in mice.” / ADVOCACY, OPINION & ANALYSIS The chair of the Idaho Republican Party said patients should have a “right to try” medical cannabis if their doctor sees a benefit. The American Civil Liberties Union is calling on Congress to build on President Donald Trump’s marijuana rescheduling move by passing legalization legislation. / BUSINESS Vireo Growth Inc. is acquiring Eaze Inc. NJ Leaf workers in North Brunswick, New Jersey voted to unionize. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Federal cannabis legalization commission proposed under Senate bill (Newsletter: December 24, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Helpful — I valued the transparency on player complaint resolution timelines. Quick, fair resolution processes prevent toxic situations from escalating. Real votes showed which teams are responsive. 오피가이드

However, many Lucknow Call Girls providers need to be more reliable and professional, as they often deceive their clients with misleading photos and information. This is the reason the call girl sector is a topic of intense discussion in dating services.

Finding out that groups like Women Grow and Tokativity are actively using social media and meetups to change perceptions in the cannabis industry-it’s inspiring! Imagine reading this while waiting for my morning coffee, it’s a boost of motivation! @Banana AI

115. 5-MeO-DMT Experience Explained A grounded conversation on the 5-MeO-DMT experience—how it affects the nervous system, how it differs from DMT, and why safety and integration matter. Episode Summary What is 5-MeO-DMT, and why do people describe it so differently from other psychedelics? In this episode, April Pride sits down with licensed clinicians and facilitators Roger and Dustin to explore the 5-MeO-DMT experience through both lived experience and emerging neuroscience. Often referred to as the God molecule psychedelic, 5-MeO-DMT is widely described as a non-visual psychedelic experience—one that quiets the nervous system rather than amplifying imagery, stories, or symbols. Together, they break down 5-MeO-DMT vs DMT, explain how this compound interacts with serotonin receptors in the brain, and discuss why many people report profound ego dissolution, nervous system regulation, and long-term shifts in how they experience safety and connection. This episode also centers women and psychedelics, examining why women—particularly those who have spent years in control, caretaking, or emotional labor—may feel especially drawn to this form of surrender-based medicine. If you’re seeking grounded insight into psychedelic harm reduction, integration after 5-MeO-DMT, and what makes this medicine fundamentally different from other psychedelic experiences, this conversation is an essential listen. Key Takeaways The 5-MeO-DMT experience is often felt rather than seen, with little to no visuals or narrative content Unlike classic psychedelics, 5-MeO-DMT is widely described as a non-visual psychedelic experience Understanding 5-MeO-DMT vs DMT is critical—many vape pens labeled “DMT” contain N-N-DMT, not 5-MeO-DMT 5-MeO-DMT strongly activates both 5-HT2A and 5-HT1A serotonin receptors, impacting cognition and nervous system regulation The medicine often quiets the nervous system rather than stimulating imagery or meaning-making Synthetic 5-MeO-DMT allows for more precise dosing and supports harm reduction by protecting the Sonoran Desert toad Women may experience particular resonance due to lifelong patterns of regulation, control, and emotional labor Psychedelic integration after 5-MeO-DMT is essential; the effects unfold over time, not just during the session Screening, contraindications, and aftercare are non-negotiable components of responsible psychedelic use Timestamps [00:00] What people mean when they describe the God molecule psychedelic [02:10] How Roger and Dustin came to work with 5-MeO-DMT [03:36] Why this is a non-visual psychedelic experience [04:22] Synthetic vs toad-derived 5-MeO-DMT and harm reduction [06:57] Why some therapeutic “stuckness” responds differently to 5-MeO-DMT [08:28] Serotonin receptors and psychedelics: the double-door explanation [10:00] Nervous system regulation and surrender, especially for women [11:14] Gamma brainwaves, endogenous release, and embodied remembering [13:41] April’s experience with DMT vapes and common confusion [16:19] Clear distinctions between 5-MeO-DMT vs DMT [18:30] Health risks, medications, and serotonin syndrome [20:30] Ketamine, DMT, and the limits of comparison [22:53] Why women and psychedelics intersect uniquely here [23:21] Integration, meaning-making, and what comes after the experience Guests Roger & DustinLicensed clinicians and facilitators at Sky Mountain Retreats, specializing in carefully screened, harm-reduction-focused 5-MeO-DMT experiences with an emphasis on preparation, precision dosing, and long-term integration. Additional Resources SetSet Psychedelic Cards Women in the Wild application Learn more about this episode: https://aprilpride.substack.com/p/5-meo-dmt-experience-nervous-system-safety Hosted by April Pride Subscribe for April’s newsletter on Substack at https://aprilpride.substack.com/subscribe or at getsetset.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset Get full access to SetSet with April Pride at aprilpride.substack.com/subscribeCatch the full episode here

Another holiday season has arrived—and, with it, another round of public service announcements from regulators in states that have legalized marijuana that are aimed at advising people about how to comply with the law and stay safe amid the merriment. This has become something of a trend over recent years, with states increasingly using the annual occasion to promote messaging focused on education over stigma to help cannabis consumers better understand the laws—particularly around impaired driving—while also offering advice to prevent overindulgence. This year, cannabis regulators in New Jersey and Virginia have put out holiday-themed social media and blog posts about safe consumption practices. “The holidays are a time for food, fun, laughter, and connecting with the people who make life sweeter,” the New Jersey Cannabis Regulatory Commission (NJ-CRC) said. “And as more adults in New Jersey choose to enjoy, or gift legal cannabis during the season, the NJ-CRC has launched its second safe-use campaign, S.M.A.R.T., to help keep celebrations (relatively) stress-free.” The acronym stands for “Safe, Mindful, Aware, Responsible and Thoughtful.” “S.M.A.R.T. is an easy way to remember the basics of responsible cannabis use, especially when travel is constant, roads are chaotic, homes are busy, and curious little ones are wandering,” the officials said. “Whether you’re a host, a guest, a first-time weed shopper, someone who already knows their way around a dispensary, or can roll up with one hand, being S.M.A.R.T. helps everyone to relax and enjoy the season,” the state blog post says. “Be Safe. Be Mindful. Be Aware. Be Responsible. Be Thoughtful. Be S.M.A.R.T. this holiday season.” Wishing you a holiday season filled with love, happiness, and good vibes. If cannabis is a part of your celebration, keep it away from kids, use in moderation, and don’t drive high. pic.twitter.com/iTRWhB3nAG — New Jersey Cannabis Regulatory Commission (@NewJerseyCRC) December 22, 2025 On X, NJ-CRC emphasized that people who use marijuana in compliance with state law should not drive after using cannabis, ensure that marijuana products are kept away from children and practice moderation. Virginia’s Cannabis Control Authority (CCA), meanwhile, shared a post stressing the importance of understanding the state’s unique marijuana law, particularly as it concerns “gifting.” Planning to give the gift of green this year? (wink*wink*) Before you do, make sure you’re doing it legally. We break down legal adult exchanges of cannabis: https://t.co/ELOe9YUjNV pic.twitter.com/VCGNmDF91f — Virginia Cannabis Control Authority (@Virginia_CCA) December 4, 2025 Possession, as well as non-commercial gifting, of cannabis is permitted under the current law in Virginia. But there are certain policy parameters to keep in mind as lawmakers look to 2026 to establish a retail market under an incoming pro-reform governor. “While ‘adult sharing’ of cannabis between people 21 years and older is legal in Virginia, this term only applies to specific situations. Other exchanges may be illegal and can carry penalties. Common illegal exchanges are known as ‘gifting schemes,'” the CCA’s guidance says. “‘Gifting’ cannabis to someone as part of the sale of another good or service, like a sticker or seminar” is not legal, it says. Several other states—from California to New York—have also historically publicized public education campaigns around the holidays in recent years. About one in three Americans say their holiday “pregame” routine involves using marijuana, according to a new survey. Mainstream media outlets this past November also picked up on a trend that’s long been practiced within the cannabis community: the “cousin walk,” a Thanksgiving pre-game (and usually pre-dinner) tradition for some where the typically younger adults at a gathering will sneak away for a cannabis break before the feast begins. The post State Marijuana Regulators Share Tips On How To Stay Safe And Legal Around The Holidays appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Attorneys general for 19 states and Washington, D.C. are siding with the federal government in a U.S. Supreme Court case that could decide the fate of a law preventing marijuana users from buying or possessing firearms. In an amicus brief for the case U.S. v. Hemani that was submitted to the court on Friday, the top state prosecutors—led by Illinois Attorney General Kwame Raoul (D)—said justices should maintain the current statute known as 18 U.S.C. § 922(g)(3). That law has been challenged in multiple federal courts in recent years, but the Supreme Court agreed to take up Hemani, a case that led a lower court to rule that the federal prohibition on gun ownership by people who use cannabis violates the Second Amendment of the U.S. Constitution. “I am urging the Supreme Court to reverse the appellate court’s decision because the mix of habitual drug use and firearms poses recognized public safety risks,” Raoul said in a press release. “Allowing habitual drug users to carry or use firearms significantly increases danger to our communities.” “I am proud to lead this bipartisan coalition, as we all agreed we need to work together to protect our states and communities from gun violence,” he said. In the brief, the attorneys general—most of which represent states that have enacted adult-use legalization within their borders—said they have a “substantial interest in the health, safety, and welfare of their communities, which includes preventing firearms from coming into the hands of people likely to misuse them.” “That interest is implicated by this case, which addresses the extent to which the federal government may prohibit an individual who is an ‘unlawful user of or addicted to any controlled substance’ from possessing firearms,” they said. The brief doesn’t focus singularly on the marijuana and gun issue, which can be partly explained by the fact that the defendant in the case was not only a cannabis consumer but also a user of cocaine who’s sold drugs in the past, according to court findings. But the impact of a ruling would likely have substantial implications for marijuana consumers and patients. The reasoning that other courts have used to deem the firearm ban unconstitutional is “flawed in multiple respects,” the attorneys general said, “including that it misdescribes the scope of the relevant historical tradition, misapplies this Court’s precedents, and unduly ties the hands of legislatures seeking to protect the public from the full range of dangers associated with combining firearms and drugs.” While the district court in Hemani argued that gun statutes should distinguish between people who are actively impaired from controlled substances and drug users who don’t possess guns while intoxicated, the latter group, the brief says that “habitual drug use can cause some individuals to experience chronic psychological disturbances that affect their conduct and decision-making in a manner that compromises their ability to safely handle firearms.” “Further, because much drug use is illicit, habitual drug users frequently interact with the illegal drug trade, which is inherently dangerous,” it says. The brief cites a related case, U.S. v. Harris, where a regular cannabis user lost his gun after becoming intoxicated and the weapon ended up in the hands of a felon who was prohibited from possessing firearms. “In short, amici States have a substantial interest in retaining the flexibility to address new societal concerns with appropriately tailored firearms regulations that are consistent with the principles underlying this country’s historical tradition. Section 922(g)(3), as well as its state counterparts, respect that balance.” Crime trends across the country show that the “altered mental states caused by these and other drugs can be dangerous when combined with firearms, even when an individual user does not necessarily intend violence or harm or even fire the weapon,” the state officials said. Other signatories of the amicus brief include the attorneys general of California, Colorado, Connecticut, Delaware, Hawaii, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Jersey, New York, Ohio, Oregon, Rhode Island, Vermont, Washington State and Washington, D.C. Notably, all of those states have legalized adult-use marijuana, with the exception of Hawaii, where only medical cannabis is legal. “Drugs and guns are a dangerous combination,” California Attorney General Rob Bonta (D) said. “Potentially dangerous drug users should not possess firearms—this is a commonsense notion to prevent people who use drugs from harming themselves, their loved ones, or their communities.” “Both red and blue states alike—recognizing the dangers posed by combining habitual drug use with firearms—have imposed firearm restrictions to prevent gun violence,” he said, adding that justices should “reverse a lower court decision, uphold public safety, and keep firearms out of the reach of people who are drug users.” Several other briefs were also submitted on Friday to justices in the case, which was granted cert last month. Firearm control groups including Everytown for Gun Safety, Second Amendment Law Scholars, Brady Center to Prevent Gun Violence, Giffords Law Center to Prevent Gun Violence and Global Action on Gun Violence have told the Supreme Court to overturn the lower court’s ruling in the matter, for example. A coalition of history and law professors also submitted a brief. Also last week, Smart Approaches to Marijuana (SAM) and 21 other prohibitionist groups filed a brief, urging justices to uphold the constitutionality of the federal gun ban for people who use cannabis—which they claim is associated with violence and psychosis. U.S. Solicitor General D. John Sauer, for his part, told the Supreme Court that people who use illegal drugs “pose a greater danger” than those who drink alcohol. The latests amicus briefs were filed just one day after President Donald Trump signed an executive order directing U.S. Attorney General Pam Bondi to expeditiously complete a rulemaking process to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). It’s uncertain to what extent, if at all, the modest policy change would impact the pending gun cases. Meanwhile, the Biden administration was evidently concerned about potential legal liability in federal cases for people convicted of violating gun laws simply by being a cannabis consumer who possessed a firearm, documents recently obtained by Marijuana Moment show. The previously unpublished 2024 guidance from former President Joe Biden’s Justice Department generally cautioned U.S. attorneys to use discretion in prosecuting federal cannabis cases, particularly for offenses that qualified people for pardons during his term. But one section seems especially relevant as the Supreme Court takes on a case challenging the constitutionality of the current federal gun statute. With respect to Hemani, in a separate August filing for the case, the Justice Department also emphasized that “the question presented is the subject of a multi-sided and growing circuit conflict.” In seeking the court’s grant of cert, the solicitor general also noted that the defendant is a joint American and Pakistani citizen with alleged ties to Iranian entities hostile to the U.S., putting him the FBI’s radar. Now that the Supreme Court has agreed to take up Hemani, if justices declare 922(g)(3) constitutional, such a ruling could could mean government wins in the remaining cases. The high court last month denied a petition for cert in U.S. v. Cooper, while leaving pending decisions on U.S. v. Daniels and U.S. v. Sam. The court also recently denied a petition for cert in another gun and marijuana case, U.S. v. Baxter, but that wasn’t especially surprising as both DOJ and the defendants advised against further pursing the matter after a lower court reinstated his conviction for being an unlawful user of a controlled substance in possession of a firearm. Meanwhile, in recent interviews with Marijuana Moment, several Republican senators shared their views on the federal ban on gun possession by people who use marijuana—with one saying that if alcohol drinkers can lawfully buy and use firearms, the same standard should apply to cannabis consumers. Separately, the U.S. Court of Appeals for the Tenth Circuit earlier this year sided with a federal district court that dismissed an indictment against Jared Michael Harrison, who was charged in Oklahoma in 2022 after police discovered cannabis and a handgun in his vehicle during a traffic stop. The case has now been remanded to that lower court, which determined that the current statute banning “unlawful” users of marijuana from possessing firearms violates the Second Amendment of the Constitution. The lower court largely based his initial decision on an interpretation of a Supreme Court ruling in which the justices generally created a higher standard for policies that seek to impose restrictions on gun rights. In the U.S. Court of Appeals for the Eleventh District, judges recently ruled in favor of medical cannabis patients who want to exercise their Second Amendment rights to possess firearms. As a recent report from the Congressional Research Service (CRS) explained the current legal landscape, a growing number of federal courts are now “finding constitutional problems in the application of at least some parts” of the firearms prohibition. In a recent ruling, a three-judge panel for the U.S. Court of Appeals for the Eighth Circuit vacated a defendant’s conviction and remanded the case back to a district court, noting that a retrial before a jury may be necessary to determine whether cannabis in fact caused the defendant to be dangerous or pose a credible threat to others. The Third Circuit separately said in a published opinion that district courts must make “individualized judgments” to determine whether 922(g)(3) is constitutional as applied to particular defendants. A federal court in October agreed to delay proceedings in a years-long Florida-based case challenging the constitutionality of the ban on gun ownership by people who use medical marijuana, with the Justice Department arguing that the Supreme Court’s recent decision to take up Hemani warrants a stay in the lower court. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Earlier this year, a federal judge in Rhode Island ruled that the ban was unconstitutional as applied to two defendants, writing that the government failed to establish that the “sweeping” prohibition against gun ownership by marijuana users was grounded in historical precedent. A federal judge in El Paso separately ruled late last year that the government’s ongoing ban on gun ownership by habitual marijuana users is unconstitutional in the case of a defendant who earlier pleaded guilty to the criminal charge. The court allowed the man to withdraw the plea and ordered that the indictment against him be dismissed. DOJ has claimed in multiple federal cases over the past several years that the statute banning cannabis consumers from owning or possessing guns is constitutional because it’s consistent with the nation’s history of disarming “dangerous” individuals. In 2023, for example, the Justice Department told the U.S. Court of Appeals for the Third Circuit that historical precedent “comfortably” supports the restriction. Cannabis consumers with guns pose a unique danger to society, the Biden administration claimed, in part because they’re “unlikely” to store their weapon properly. Meanwhile, some states have passed their own laws either further restricting or attempting to preserve gun rights as they relate to marijuana. Recently a Pennsylvania lawmaker introduced a bill meant to remove state barriers to medical marijuana patients carrying firearms. Colorado activists also attempted to qualify an initiative for November’s ballot that would have protected the Second Amendment rights of marijuana consumers in that state, but the campaign’s signature-gathering drive ultimately fell short. As 2024 drew to a close, the ATF issued a warning to Kentucky residents that, if they choose to participate in the state’s medical marijuana program that’s set to launch imminently, they will be prohibited from buying or possessing firearms under federal law. The official said that while people who already own firearms aren’t “expected to” turn them over if they become state-legal cannabis patients, those who “wish to follow federal law and not be in violation of it” must “make the decision to divest themselves of those firearms.” Since then, bipartisan state lawmakers have introduced legislation that would urge Kentucky’s representatives in Congress to amend federal law to clarify that users of medical marijuana may legally possess firearms, though no action has since been taken on that bill. Kentucky Gov. Andy Beshear (D) said in January that he supported the legislature’s effort to urge the state’s congressional delegation to call for federal reforms to protect the Second Amendment rights of medical marijuana patients, but the governor added that he’d like to see even more sweeping change on the federal level. The post Supreme Court Should Uphold Gun Ban For Marijuana Users, 19 State AGs Tell Justices appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The head of the major gardening supply company Scotts Miracle-Gro says President Donald Trump called a proposal to move marijuana from Schedule I to Schedule II—rather than Schedule III, as he ultimately directed last week—a “half-assed” move amid “hardcore arguing” in discussions about the reform. Scotts Miracle-Gro CEO Jim Hagedorn—whose Hawthorne Gardening Company unit provides supplies for cannabis growers—told NewsNation that a two hour and 15 minute meeting in the Oval Office about rescheduling this month was “insane,” with heated debate over the policy change “led by the president.” “I could see that the president was sympathetic, but I could also see there was tension in the air. He led the meeting,” he said. “The president rightfully said, ‘We’re not doing [Schedule II]—II is a half-assed version of III. We’re doing III or we do nothing.'” Hagedorn—who said back in August that Trump had told him directly “multiple times” that he intended to see through the marijuana rescheduling process—took some credit for the president’s decision to sign an executive order directing the attorney general to complete the marijuana rescheduling process. He said that, “if it hadn’t been our willingness to stand behind it and see it through,” the Hawthorne Gardening Company would have “gone out of business.” He added that multiple cannabis companies have gone under as the reform sat in flux. The CEO was among many stakeholders to weigh in on the president’s order on rescheduling, which would not federally legalize marijuana but would send a symbolic message while loosening certain research restrictions and allow cannabis businesses to take federal tax deductions under an Internal Revenue Service (IRS) code known as 280E. “With 39 states already legalizing cannabis in some form, rescheduling to a lower level drug on the federal level has been long overdue,” he said. “President Trump deserves credit and praise for taking this bold action, as it reflects the will of the people and sets the stage for much-needed research into the medical use of cannabis.” Scotts Miracle-Gro, meanwhile, has also lobbied at the federal level on cannabis issues such as marijuana industry banking access. Trump’s decision to advance rescheduling came at the behest of other cannabis and cannabis-adjacent entrepreneurs as well, including the CEO of the multi-marijuana business Trulieve. Meanwhile, a GOP senator suggested last week that that Trump lied when he said during the signing ceremony for a marijuana rescheduling executive order that he hadn’t received any calls in opposition to the reform. During last week’s event, Trump noted strong public support for marijuana reform and said numerous people called him to voice support for cannabis rescheduling. Photo courtesy of Mike Latimer. The post Trump Rejected ‘Half-Assed’ Plan To Move Marijuana To Schedule II During ‘Insane’ Oval Office Meeting, ScottsMiracle-Grow CEO Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Teen marijuana use “remained stable” this year even as more states have enacted legalization, according to an annual federally funded survey The Monitoring the Future (MTF) survey—supported by the National Institute on Drug Abuse (NIDA) and conducted every year for decades by the University of Michigan—examines substance use trends among 8th, 10th and 12th grade students. And the latest results add to a large body of evidence contradicting prohibitionist claims that state-level legalization would drive increases in underage cannabis usage. The rate of past-year marijuana use for 12th graders was 25.7 percent, which is relatively consistent with recent years but at its lowest level since 1992. It was the same case with 10th graders, 15.6 percent of whom used marijuana in the last year. Among 8th grade students, 7.6 percent reported past-year cannabis consumption. For past-month cannabis use, that rate was 17.1 percent for 12th graders, a slight uptick from the prior year but significantly lower than its record high of 37.1 percent in 1978 before any state had legalized cannabis for adult or medical use. For 10th grade students, the rate this past year was 9.4 percent, and for 8th grade it was 4 percent—consistent with recent years. “We are encouraged that adolescent drug use remains relatively low and that so many teens choose not to use drugs at all,” NIDA Director Nora Volkow said in a press release. “It is critical to continue to monitor these trends closely to understand how we can continue to support teens in making healthy choices and target interventions where and when they are needed.” The survey also found that students who reported past-month abstention from marijuana , alcohol and nicotine were “stable for all grades” (66 percent for 12th grade, 82 percent for 10th grade and 91 percent for 8th grade). The survey also asked about the use of hemp-based cannabinoid products, including intoxicating compounds such as delta-8 THC. It found that 9 percent of 12th graders, 6 percent of 10th graders and 2 percent of 8th graders used products in that category in the past year. This year’s MTF survey was based on data from 23,726 student surveys submitted from 270 public and private schools from February-June 2025. To reform advocates, the results of the survey reinforce the idea that creating a regulatory framework for cannabis where licensed retailers must check IDs and implement other security mechanisms to prevent unlawful diversion is a far more effective policy than prohibition, with illicit suppliers whose products may be untested and where age-gating isn’t a strictly enforced regulation. To that point, a separate federally funded study out of Canada that was released last month found that that youth marijuana use rates actually declined after the country legalized cannabis. The study was released about three months after German officials released a separate report on their country’s experience with legalizing marijuana nationwide. Back in July, federal health data also indicated that while past-year marijuana use in the U.S. overall has climbed in recent years, the rise has been “driven by increases…among adults 26 years or older.” As for younger Americans, rates of both past-year use and cannabis use disorder, by contrast, “remained stable among adolescents and young adults between 2021 and 2024.” Across the U.S., research suggests that marijuana use by young people has generally fallen in states that legalize the drug for adults. A report from the advocacy group Marijuana Policy Project (MPP), for example, found that youth marijuana use declined in 19 out of 21 states that legalized adult-use marijuana—with teen cannabis consumption down an average of 35 percent in the earliest states to legalize. The report cited data from a series of national and state-level youth surveys, including the annual MTF survey. Another survey from the U.S. Centers for Disease Control and Prevention (CDC) last year also showed a decline in the proportion of high-school students reporting past-month marijuana use over the past decade, as dozens of states moved to legalize cannabis. At the state level, MPP’s assessment looked at research such as the Washington State Healthy Youth Survey that was released in April 2024. That survey showed declines in both lifetime and past-30-day marijuana use in recent years, with striking drops that held steady through 2023. The results also indicated that perceived ease of access to cannabis among underage students has generally fallen since the state enacted legalization for adults in 2012—contrary to fears repeatedly expressed by opponents of the policy change. In June of last year, meanwhile, the biannual Healthy Kids Colorado Survey found that rates of youth marijuana use in the state declined slightly in 2023—remaining significantly lower than before the state became one of the first in the U.S. to legalize cannabis for adults in 2012. The findings broadly track with other past surveys that have investigated the relationship between jurisdictions that have legalized marijuana and youth cannabis use. For example, a Canadian government report recently found that daily or near-daily use rates by both adults and youth have held steady over the last six years after the country enacted legalization. Another U.S. study reported a “significant decrease” in youth marijuana use from 2011 to 2021—a period in which more than a dozen states legalized marijuana for adults—detailing lower rates of both lifetime and past-month use by high-school students nationwide. Another federal report published last summer concluded that cannabis consumption among minors—defined as people 12 to 20 years of age—fell slightly between 2022 and 2023. Separately, a research letter published by the Journal of the American Medical Association (JAMA) in April 2024 said there’s no evidence that states’ adoption of laws to legalize and regulate marijuana for adults have led to an increase in youth use of cannabis. Another JAMA-published study earlier that month that similarly found that neither legalization nor the opening of retail stores led to increases in youth cannabis use. In 2023, meanwhile, a U.S. health official said that teen marijuana use has not increased “even as state legalization has proliferated across the country.” Another earlier analysis from the U.S. Centers for Disease Control and Prevention found that rates of current and lifetime cannabis use among high school students have continued to drop amid the legalization movement. A separate NIDA-funded study published in the American Journal of Preventive Medicine in 2022 also found that state-level cannabis legalization was not associated with increased youth use. The study demonstrated that “youth who spent more of their adolescence under legalization were no more or less likely to have used cannabis at age 15 years than adolescents who spent little or no time under legalization.” Yet another 2022 study from Michigan State University researchers, published in the journal PLOS One, found that “cannabis retail sales might be followed by the increased occurrence of cannabis onsets for older adults” in legal states, “but not for underage persons who cannot buy cannabis products in a retail outlet.” The trends were observed despite adult use of marijuana and certain psychedelics reaching “historic highs” in 2022, according to separate 2023 data. The post Teen Marijuana Use ‘Remained Stable’ As Legalization Expands, Federal Health Officials Acknowledge appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The net will be bogged straight down together with fake sites without genuine concept nevertheless the submit has been great and also worth the particular examine. Many thanks regarding revealing this kind of with me at night. free 1xbet promo code today

A Democratic senator has filed a bill aimed at laying the groundwork for federal marijuana legalization. Sen. John Hickenlooper (D-CO) introduced the legislation—titled the Preparing Regulators Effectively for a Post-Prohibition Adult-Use Regulated Environment Act (PREPARE) Act—on Thursday. The measure would direct the attorney general to create a commission charged with making recommendations on a regulatory system for cannabis that models what’s currently in place for alcohol. It was filed on the same day that President Donald Trump issued an executive order directing marijuana to be rescheduled from Schedule I to Schedule III of the Controlled Substances Act. Reps. Dave Joyce (R-OH) and House Minority Leader Hakeem Jeffries (D-NY) introduced a version of the cannabis commission bill in the House in April, and Hickenlooper has sponsored iterations of the legislation over the past two Congresses. Hickenlooper, who served as governor of Colorado when voters approved a recreational cannabis legalization initiative in 2012, which he campaigned against at the time, said in a social media post on Monday that Trump’s marijuana executive order represents “another example of Colorado blazing the trail.” “Now release and expunge records for everyone who was charged with federal marijuana crimes,” he said, “and let’s pass our bill to prepare us for federal legalization while we’re at it.” Another example of Colorado blazing the trail. Now release and expunge records for everyone who was charged with federal marijuana crimes – and let's pass our bill to prepare us for federal legalization while we're at it. pic.twitter.com/b6P9wl4H1H — Senator John Hickenlooper (@SenatorHick) December 22, 2025 Here’s what the bill would accomplish: Require the attorney general to establish a “Commission on the Federal Regulation of Cannabis” within 30 days of the bill’s enactment. The commission would be responsible for studying federal and state regulatory models for alcohol and make recommendations about how they could inform marijuana regulations. Among other things, the commission’s report must look at the impact of marijuana criminalization, particularly as it concerns minority, low-income and veteran communities. The panel would also examine the “lack of consistent regulations for cannabis product safety, use and labeling requirements,” including those related to youth safety, as well as the “lack of guidance for cannabis crop production, sale, intrastate, interstate, and international trade.“ It would also need to make recommendations on how to remedy cannabis-related banking and research barriers as well as address measures to ensure the “successful coexistence of individual hemp and cannabis industries, including prevention of cross pollination of cannabis and hemp products.” Members would further be mandated to study and make recommendations on “efficient cannabis revenue reporting and collecting, including efficient and tenable federal revenue frameworks.” The panel would be required to issue a report to Congress within 12 months. The commission would also include representatives of: Department of Health and Human Services Department of Justice Department of Agriculture Department of Veterans Affairs Department of Interior Department of Education Department of Labor Department of Treasury Department of Commerce Department of Housing and Urban Development White House Office of National Drug Control Policy National Institutes of Health Alcohol and Tobacco Tax and Trade Bureau Food and Drug Administration Internal Revenue Service Bureau of Alcohol, Tobacco, Firearms and Explosives National Highway Traffic Safety Administration Occupational Safety and Health Administration National Institute of Standards and Technology Small Business Administration U.S. Trade Representative Office of Minority Health Indian Health Service — Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — It would also include a person formerly incarcerated for a non-violent cannabis use or possession crime, a substance use disorder prevention expert, an expert on the history of marijuana criminalization, a person with knowledge about cannabis research, a representative from a trade organization or nonprofit representing highly regulated adult goods and consumer package goods and two people who have worked to develop state-level regulatory systems. Some of the appointments would be made by the attorney general, and others would come from congressional leaders. The bill also contains a stipulation that, “if after the commission is appointed there is a partisan imbalance of commission members, the congressional leaders of the political party with fewer members on the commission shall jointly name additional members to create partisan parity on the commission.” Read the full text of the new marijuana commission bill below: The post Trump’s Attorney General Would Form A Marijuana Commission To Prepare For Federal Legalization Under New Senate Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

To provide a First-time, My group is eternally visiting web based designed for articles and reviews which is in be an aid to all of us. Thanks for your time. 猛健樂副作用

Lawmakers push for more marijuana reform; MA anti-cannabis ballot signatures; NJ psilocybin vote; Poll: Americans use marijuana for holiday stress Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The U.S. Department of Transportation sent a notice clarifying that President Donald Trump’s marijuana rescheduling executive order “will not change” federal drug testing process and regulations for safety‐sensitive transportation workers—at least “until any rescheduling is complete.” Bipartisan members of Congress say that President Donald Trump’s marijuana rescheduling order is only the first step toward needed reforms—and that cannabis industry banking access, sentencing reform and full legalization should follow. The Massachusetts Secretary of the Commonwealth’s Elections Division certified that a campaign to scale back the marijuana legalization law by recriminalizing recreational sales and home grow got enough signatures to advance its initiative toward the 2026 ballot. The New Jersey Assembly Appropriations Committee approved a bill to legalize psilocybin therapy and create a regulated program for patient access. A new poll shows that nearly one in three Americans “pre-game” with marijuana before family holiday gatherings to emotionally prepare and deal with stress. / FEDERAL A Department of Veterans Affairs spokesperson said marijuana rescheduling won’t allow the agency’s doctors to prescribe medical cannabis but will make it easier to conduct research on marijuana. Former Deputy Assistant Secretary of Defense for Counternarcotics and Stabilization Policy James Saenz co-authored an op-ed criticizing the Trump administration’s military strikes on alleged drug boats. Sen. Cynthia Lummis (R-WY) said she disagrees with President Donald Trump on marijuana rescheduling. Sen. Tom Cotton (R-AR) and Rep. Andy Harris (R-MD) praised the recently approved federal recriminalization of hemp THC products. Rep. Pete Sessions (R-TX) said the White House rejected his request for a meeting with President Donald Trump to express his concerns about marijuana rescheduling. Rep. Greg Steube (R-FL) discussed the benefits of rescheduling marijuana. Former Rep. Matt Gaetz (R-FL) said President Donald Trump “delivered” on marijuana rescheduling when “Obama couldn’t get it done” and “Biden couldn’t get it done.” / STATES California’s attorney general touted efforts to eradicate illegal marijuana plants. Separately, regulators announced a recall of marijuana products due to the company operating as a distributor without a distributor license. A Pennsylvania representative said she is “not going to ever support legalization of recreational marijuana.” Arizona regulators filed changes to marijuana rules. Illinois regulators are proposing changes to marijuana dispensary rules. Colorado regulators published a bulletin about burglaries against marijuana businesses. Oklahoma regulators published guidance about requirements for physicians who want to recommend medical cannabis. Michigan regulators signed a cannabis compact with the Pokagon Band of Potawatomi Indians of Michigan and Indiana. Texas officials awarded $50 million to UTHealth Houston and the University of Texas Medical Branch at Galveston to support ibogaine therapy trials. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / SCIENCE & HEALTH A review concluded that “CBD is a valuable antioxidant agent in skin care science.” A study found that “cognitive performance improved two weeks after receiving psilocybin-assisted psychotherapy.” / ADVOCACY, OPINION & ANALYSIS Former Republican National Committee Communications Director Kevin Heye said President Donald Trump’s marijuana rescheduling order sends a “mixed message.” The Heritage Foundation criticized President Donald Trump’s move to reschedule marijuana. Gun Owners of America tweeted, “President Trump just ordered that marijuana be reclassified from Schedule I to Schedule III. GOA is calling on ATF to cease treating Americans who are prescribed marijuana as ‘unlawful users of controlled substances’ & federally prohibited from possessing firearms.” / BUSINESS Atai Beckley N.V. received a U.S. patent for its oral R-MDMA medication. Canadian retailers sold C$451.7 million worth of legal marijuana products in October. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Mike Latimer. The post Will cannabis rescheduling affect drug testing for safety-sensitive workers? (Newsletter: December 23, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Helpful — I valued the transparency on player complaint resolution timelines. Quick, fair resolution processes prevent toxic situations from escalating. Real votes showed which teams are responsive. slot1000 Excellent roundup — I appreciated the filter for low-population but active servers. Smaller communities often offer friendlier vibes and cooperation. Real player rankings showed which small servers thrive. koi toto Excellent list — the server comparison tools simplified my decision. Side-by-side stats like drop rates and population were priceless. Real votes added the final confirmation. ταρω

In the form of Inexperienced, Now i'm once and for good seeking via the internet just for articles or reviews which has been about help others. With thanks. resorts for sale in the caribbean

This is exactly the text I'm sure uncovering everywhere you look. Thanks a lot for a blog page, I just join up your website. That is the decent blog page. inches. resorts for sale in the caribbean

My spouse and i shocked while using investigation anyone created to choose this certain release outstanding. Amazing task! resorts for sale in the caribbean

This can be a excellent ideas particularly in order to individuals a new comer to blogosphere, short as well as precise information… Many thanks with regard to discussing that one. Essential study post. resorts for sale in the caribbean